
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
The future of commercialization extends beyond product promotion and patient acquisition. Learn how Direct-to-Disease models enable pharmaceutical companies to build trusted, digitally enabled ecosystems that improve access, adherence, and long-term outcomes.






